Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Total Debt (2024 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Total Debt for 2 consecutive years, with $115.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Debt rose 22.41% year-over-year to $115.8 million, compared with a TTM value of $115.8 million through Dec 2025, up 22.41%, and an annual FY2025 reading of $115.8 million, up 22.41% over the prior year.
  • Total Debt was $115.8 million for Q4 2025 at Karyopharm Therapeutics, up from $96.4 million in the prior quarter.
  • Across five years, Total Debt topped out at $115.8 million in Q4 2025 and bottomed at $93.5 million in Q2 2024.